Verastem Oncology Reports Results of Copiktra (Duvelisib) in P-III DUO Study in Patients with R/R CLL/SLL

 Verastem Oncology Reports Results of Copiktra (Duvelisib) in P-III DUO Study in Patients with R/R CLL/SLL

Verastem Oncology Reports Results of Copiktra (Duvelisib) in P-III DUO Study in Patients with R/R CLL/SLL

Shots:

  • The P-III DUO study involves assessing of Copiktra (Duvelisib) vs ofatumumab in 319 patients with r/r CLL (n=312)/SLL (n=7) after at least two prior therapies in ratio 1:1
  • The P-III study results: ORR (78% vs 39%); PFS (16.4mos. vs 9.1 mos.); presented at 23rd Annual International Congress on Hematologic Malignancies
  • Copiktra(25mg, q2d) is an oral inhibitor of PI3Ki (phosphoinositide 3-kinase), first approved dual inhibitor of PI3K-delta and PI3K-gamma. On 24 Sept,2018, Copiktra received FDA’s approval for r/r CLL/SLL and accelerated approval for r/r follicular lymphoma (FL)

Click here to read full press release/ article | Ref: Verastem Oncology | Image: Verastem Oncology

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post